The facility will manufacture Specialty and Fine Chemicals tailored to various applications across industries such as Polymer and Water Treatment facilities
The validations confirm the completion of the applications and commence the scientific review process
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty
Acquisition of exclusive commercialization rights for European markets
Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months
Launch of Indian public health standards for Ayush healthcare facilities
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
The product will be launched in March 2024
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
